Arena Pharmaceuticals, Inc. (ARNA)
| Market Cap | 3.88B |
| Revenue (ttm) | 57,000 |
| Net Income (ttm) | -422.94M |
| Shares Out | 59.78M |
| EPS (ttm) | -7.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $63.27 |
| Previous Close | $64.79 |
| Change ($) | -1.52 |
| Change (%) | -2.35% |
| Day's Open | 64.05 |
| Day's Range | 63.00 - 64.63 |
| Day's Volume | 328,201 |
| 52-Week Range | 44.79 - 90.19 |
Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of 9.59% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the st...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals will report first quarter 2021 financial results on May 5, and will host a live Q&A with the investment community at 4:30 pm...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #AADVMX2021--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the American Academy of Dermatology VMX E...
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today announced its second annual ESG report, outlining the Company's long-term commitment to the betterment of society.
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals to present data from the Phase 2b ADVISE trial at the American Academy of Dermatology VMX on Friday, April 23.
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021, the Compensation Committee of its Board of Directors granted to 17 ne...
Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock?
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock opti...
Can this pharma blow past its highs from 10 years ago, or will it fade away -- again?
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will conti...
Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVAT...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will cont...
Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 19.32% year over year to ($2.10), which m...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended D...
On Tuesday, February 23, Arena Pharmaceuticals (NASDAQ:ARNA) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will cont...
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees ind...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #earnings--Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23.
SAN DIEGO--(BUSINESS WIRE)-- #ArenaPharm--Industry veteran Garry Neil, MD named Board Chair. Nawal Ouzren, CEO of Sensorion named to Board.
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will deve...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and effica...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will deve...
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employees induce...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis industry ...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis industry ...
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to present virt...
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to five new em...
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly sel...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in the upcomi...
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 3rd Annual Evercore ISI HealthCONx Conference (Transcript)
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals announces the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer.
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in the upcomi...
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 13 new empl...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in th...
The biotech posted clinical trial data that left more to be desired.
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.
Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2020 Results - Earnings Call Transcript
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) decreased 19.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 15.75% over the past year to ($1.69...
SAN DIEGO, Calif., Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2020...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-...
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smar...
Arena Pharmaceuticals has an impressive pipeline of compounds, and its trials are progressing well now, despite the impact of COVID-19. After its equity offering in early June at $50 per share, shares t...
SAN DIEGO, Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from the Phase 2 OASIS trial and its open-label extension for its investigative drug candidate et...
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Jefferies Next Generation IBD Therapeutics Virtual Summit Call Transcript
About ARNA
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the tr... [Read more...]
| Industry Biotechnology | IPO Date Jul 28, 2000 |
| CEO Amit Munshi | Employees 363 |
| Stock Exchange NASDAQ | Ticker Symbol ARNA |
Analyst Forecasts
According to 14 analysts, the average rating for ARNA stock is "Strong Buy." The 12-month stock price forecast is 98.07, which is an increase of 55.00% from the latest price.